MIRA Pharmaceuticals, Inc. (MIRA)
$0.67-5.63%Close
SELLCRISIS · day 2
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $28M
- Beta
- 1.49
- P/E (TTM)
- -0.48
- Short % float
- 1.52%
- Days to cover
- 2.4
- SI change
- -8.7%
- 1W
- -5.63%
- 1M
- -10.67%
- vs SPY 1W
- -5.50%
- vs SPY 1M
- -13.17%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 5
- VALUE
- 5
- GROWTH
- 39
- GARP
- 0
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC-64.2%
REV YoY-
ROE-107.0%
EPS YoY-
ROA-115.6%
GROSS0
OP0
NET0
[VALUATION]
P/E TTM-0.48
P/E FWD-
SECTOR PE20.34
INDUSTRY PE10.09
P/B3.43
P/FCF-
EV/EBITDA-2.59
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E-
ALTMAN Z-
CURR RATIO200.08
ND/EBITDA-
BETA1.49
Company news
FAQ
- What is LOPJLB’s current signal on MIRA?
- LOPJLB’s latest quantitative signal on MIRA Pharmaceuticals, Inc. (MIRA) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is MIRA in?
- MIRA Pharmaceuticals, Inc. (MIRA) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does MIRA Pharmaceuticals, Inc. (MIRA) do?
- MIRA Pharmaceuticals, Inc. operates as a biopharmaceutical enterprise currently in the clinical development phase. Its main objective involves the creation and market introduction of a novel synthetic tetrahydrocannabinol (THC) analog. This compound is undergoing investigation for its potential to address anxiety and the cognitive impairments frequently observed in adult patients suffering from…